Sign In
Buy LUCD
Lucid Diagnostics Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0700 |
| EPS Surprise | -40.00% |
| Revenue estimate | 1.38M |
| Revenue actual | 1.256M |
| Revenue Surprise | -9.00% |
| Release date | Mar 25, 2026 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.100 |
| EPS Surprise | -42.86% |
| Revenue estimate | 1.363M |
| Revenue actual | 1.504M |
| Revenue Surprise | 10.35% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.100 |
| EPS Surprise | -66.67% |
| Revenue estimate | 1.388M |
| Revenue actual | 1.211M |
| Revenue Surprise | -12.74% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.100 |
| EPS Surprise | -11.11% |
| Revenue estimate | 1.712M |
| Revenue actual | 1.163M |
| Revenue Surprise | -32.08% |
Last 4 Quarters for Lucid Diagnostics
Below you can see how LUCD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $0.98 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.100 |
| EPS surprise | -11.11% |
| Date | Price |
|---|---|
| Aug 07, 2025 | $0.98 |
| Aug 08, 2025 | $1.00 |
| Aug 11, 2025 | $1.00 |
| Aug 12, 2025 | $1.00 |
| Aug 13, 2025 | $0.98 |
| Aug 14, 2025 | $0.98 |
| Aug 15, 2025 | $1.02 |
| Aug 18, 2025 | $1.02 |
| Aug 19, 2025 | $0.99 |
| 4 days before | 0.0306% |
| 4 days after | 1.28% |
| On release day | 0% |
| Change in period | 1.32% |
| Release date | Nov 12, 2025 |
| Price on release | $1.11 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.100 |
| EPS surprise | -66.67% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $1.07 |
| Nov 07, 2025 | $1.08 |
| Nov 10, 2025 | $1.05 |
| Nov 11, 2025 | $1.04 |
| Nov 12, 2025 | $1.11 |
| Nov 13, 2025 | $1.07 |
| Nov 14, 2025 | $1.07 |
| Nov 17, 2025 | $1.07 |
| Nov 18, 2025 | $1.05 |
| 4 days before | 3.74% |
| 4 days after | -5.41% |
| On release day | -3.60% |
| Change in period | -1.87% |
| Release date | Mar 25, 2026 |
| Price on release | $1.19 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.100 |
| EPS surprise | -42.86% |
| Date | Price |
|---|---|
| Mar 19, 2026 | $1.28 |
| Mar 20, 2026 | $1.25 |
| Mar 23, 2026 | $1.25 |
| Mar 24, 2026 | $1.20 |
| Mar 25, 2026 | $1.19 |
| Mar 26, 2026 | $1.15 |
| Mar 27, 2026 | $1.12 |
| Mar 30, 2026 | $1.15 |
| Mar 31, 2026 | $1.15 |
| 4 days before | -7.03% |
| 4 days after | -3.36% |
| On release day | -3.36% |
| Change in period | -10.16% |
| Release date | May 14, 2026 |
| Price on release | $1.02 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0700 |
| EPS surprise | -40.00% |
| Date | Price |
|---|---|
| May 08, 2026 | $1.03 |
| May 11, 2026 | $1.02 |
| May 12, 2026 | $1.04 |
| May 13, 2026 | $1.02 |
| May 14, 2026 | $1.02 |
| May 15, 2026 | $0.99 |
| May 18, 2026 | $0.96 |
| May 19, 2026 | $0.95 |
| May 20, 2026 | $1.00 |
| 4 days before | -0.97% |
| 4 days after | -1.96% |
| On release day | -2.83% |
| Change in period | -2.91% |
Lucid Diagnostics Earnings Call Transcript Summary of Q1 2026
Lucid Diagnostics reported 3,177 EsoGuard tests in Q1 2026 with recognized revenue of $1.3M (billable value ~ $8.7M). The company completed an underwritten public offering (~$16.8M proceeds) and had pro forma cash of approximately $44.8M as of April 24, extending runway well into 2027. Management reiterated confidence in a favorable Medicare LCD outcome (while acknowledging logistical delays) and emphasized ongoing commercial activity: VA rollout (first PO received), engagement with health systems, a forthcoming laboratory benefit manager (LBM) coverage policy, and other payer discussions. Revenue recognition remains constrained by reimbursement uncertainty (many commercial/Medicare claims recognized on collection), with government (Medicare/MA) tests representing ~13% of volume in Q1. Quarterly cash burn averaged ~$11.3M (Q1 slightly higher at ~$12.1M) and non‑GAAP OpEx (~$11.7M) is roughly in line with recent quarters. Management continues investment in commercial and market-access capabilities while limiting overall OpEx expansion, and maintains active data-generation and clinical study programs.
